Increased 5α-Reductase Type 2 Expression in Human Breast Carcinoma following Aromatase Inhibitor Therapy: The Correlation with Decreased Tumor Cell Proliferation

Hormones and Cancer

Volumn 2, Issue 1, 2011, Pages 73-81

  Chanplakorn, Niramol ^a,b   Chanplakorn, Pongsthorn ^b   Suzuki, Takashi ^a   Ono, Katsuhiko ^a   Wang, Lin ^a   Chan, Monica S M ^a,c   Wing, Loo ^a,c   Yiu, Christopher C P ^a,c   Wing Cheong Chow, Louis ^c   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIMED Medical Institute   (China)

Author keywords

5 reductase; Androgen; Androgen receptor; Aromatase inhibitor; Breast cancer; Ki67

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE 5; ANDROGEN RECEPTOR; CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; KI 67 ANTIGEN; LETROZOLE; PROGESTERONE RECEPTOR; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN SYNTHESIS; ARTICLE; BREAST CARCINOMA; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

17-HYDROXYSTEROID DEHYDROGENASES; 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOADJUVANT THERAPY; NITRILES; PYRAZOLES; RECEPTORS, ANDROGEN; SULFONAMIDES; TREATMENT OUTCOME; TRIAZOLES;

EID: 78751580474     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-010-0062-2     Document Type: Article

References (36)

1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ (2007) Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society. Available at: http://www. cancer. org/docroot/STT/STT_0. asp. Accessed 19 Nov 2009.
2. American Cancer Society (2009) Breast Cancer Facts & Figures 2009-2010. Atlanta, GA: American Cancer Society. Available at: http://www. cancer. org/docroot/STT/STT_0. asp. Accessed Nov 2009.
3. Pasqualini JR, Chetrite GS (2005) Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 93: 221-236.
4. Sasano H, Nagasaki S, Miki Y, Suzuki T (2009) New developments in intracrinology of human breast cancer estrogen sulfatase and sulfotransferase. Ann NY Acad Sci 1155: 76-79.
5. Miller WR, Forrest AP (1974) Oestradiol synthesis by a human breast carcinoma. Lancet 2: 866-868.
6. Miller WR, Anderson TJ, White S, Larionov A, Murray J, Evans D, Krause A, Dixon JM (2005) Aromatase inhibitors: cellular and molecular effects. J Steroid Biochem Mol Biol 95: 83-89.
7. Geisler J (2008) Aromatase inhibitors: from bench to bedside and back. Breast Cancer 15: 17-26.
8. Geisler J, Lønning PE (2005) Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res 11: 2809-2821.
9. Chen S, Masri S, Hong YY, Wang X, Phung S, Yuan YC, Wu X (2007) New experimental models for aromatase inhibitor resistance. J Steroid Biochem Mol Biol 106: 8-15.
10. Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A (2006) Role of Androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 66(15): 7775-7782.
11. Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin SX, Pelletier G (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24: 152-182.
12. Lippman M, Bolan G, Huff K (1976) The effect of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4610-4618.
13. Miller WR, McDonald D, Forrest AP, Shivas AA (1973) Metabolism of androgens by human breast tissue. Lancet 1: 912-913.
14. Sonne-Hansen K, Lykkesfeldt AE (2005) Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. J Steroid Biochem Mol Biol 93: 25-34.
15. Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H (2003) Androgen receptors frequently are expressed in breast carcinomas. Cancer 98: 703-711.
16. Sasano H, Suzuki T, Miki Y, Moriya T (2008) Intracrinology of estrogens and androgens in breast carcinoma. J Steroid Biochem Mol Biol 108: 181-185.
17. Suzuki T, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamakuchi Y, Hayashi S, Sasano H (2006) 5α-Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Int J Cancer 120: 285-291.
18. Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan SMM, Miki Y, Saji S, Ueno T, Toi M, Sasano H (2010) Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat 120(3): 639-648.
19. Takagi K, Miki Y, Nagasaki S, Hirakawa H, Onodera Y, Akahira J, Ishida T, Watanabe M, Kimijima I, Hayashi S, Sasano H, Suzuki T (2010) Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocr-Relat Cancer 17(2): 415-430.
20. Chow LWC, Yip AYS, Loo WTY, Lam CK, Toi M (2008) Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 111: 13-17.
21. Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ (2006) Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 94: 1051-1056.
22. Yamashita H, Takahashi S, Ito Y, Yamashita T, Yoshiaki A, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H (2009) Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 100: 2028-2033.
23. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H (2000) 17beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br J Cancer 82: 518-523.
24. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JFR, Blamey RW, Nicholson RI (1989) Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59: 943-947.
25. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481.
26. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145.
27. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and Her-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 23: 2477-2492.
28. Suzuki T, Darnel AD, Akahira J, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T, Sasano H (2001) 5 alpha reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J Clin Endocrinol Metab 86: 2250-2257.
29. Spinola PG, Marchetti B, Mérand Y, Bélanger A, Labrie F (1988) Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors. Breast Cancer Res Treat 12: 287-296.
30. Poulin R, Baker D, Labrie F (1988) Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 12: 213-225.
31. van Gils CH, Onland-Moret C, Roest M, van Noord PAH, Peeters PHM (2003) The V89L polymorphism in the 5-α-reductase type 2 gene and risk of breast cancer. Cancer Epidemiol Biomark Prev 12: 1194-1199.
32. van L-T, Bélanger A, Labrie F (2008) Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 22(2): 207-221.
33. Wiebe JP, Lewis MJ, Cialacu V, Pawlak KJ, Zhang G (2005) The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics. J Steroid Biochem Mol Biol 93: 201-208.
34. Lewis MJ, Wiebe JP, Heathcote JG (2004) Expression of progesterone metabolizing genes (AKR1C1, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4: 27. doi: 10. 1186/1471-2407/4/27.
35. Recchione C, Venturelli E, Manzari A, Cavalleri A, Martinetti A, Secreto G (1995) Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. J Steroid Biochem Mol Biol 52: 541-546.
36. Thiantanawat A, Long BJ, Brodie AM (2003) Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 63: 8037-8050.